ReviewFrom microcirculation to cardiac event: protection with PreteraxCamici, Paolo GAuthor Information Medical Research Council Clinical Sciences Centre and National Heart and Lung Institute, Imperial College, London, UK Correspondence to Paolo G. Camici MD, FRCP, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK Tel: +44 20 8383 3186; fax: +44 20 8383 3742; e-mail: firstname.lastname@example.org Conflicts of interest: The author declares that he acts as a consultant for Servier and General Electric Health Care. Journal of Hypertension: June 2008 - Volume 26 - Issue - p S8-S10 doi: 10.1097/01.hjh.0000320753.31109.bc Buy Metrics Abstract Several studies have demonstrated that abnormalities in the function and structure of the coronary microcirculation occur in many clinical conditions, including arterial hypertension in which it might contribute to cardiovascular morbidity and mortality. This dysfunction is caused by remodelling of vascular and extravascular structures as well as abnormal coronary haemodynamics. Whether antihypertensive treatment can lead to reverse remodelling of the coronary microvasculature remains to be determined. The preliminary results of a recent study in patients with arterial hypertension and left ventricular hypertrophy show that 6 months' treatment with a combination of perindopril and indapamide is accompanied by a significant decrease in blood pressure and left ventricular mass and an increase in resting and hyperaemic myocardial blood flow measured non-invasively with positron emission tomography. This suggests that coronary microvascular dysfunction can be reversed by treatment with these drugs and might contribute to the prevention of ischaemic heart disease in these patients. © 2008 Lippincott Williams & Wilkins, Inc.